ALX Oncology Holdings Inc. ALXO

ALXO Company Overview

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology therapies designed to help the immune system recognize and destroy cancer cells. The company primarily operates in the biotechnology and oncology therapeutics industries, with a strategic emphasis on therapies targeting the CD47 pathway, a signaling mechanism used by cancer cells to evade immune detection. ALX Oncology’s lead product candidate is evorpacept (ALX148), an engineered fusion protein intended to block CD47 while minimizing hematologic toxicities associated with earlier CD47-targeting therapies. The company’s development programs are concentrated in solid tumors and hematologic malignancies, often in combination with established anti-cancer therapies such as monoclonal antibodies and checkpoint inhibitors.

The company was founded in 2015 and is headquartered in South San Francisco, California. ALX Oncology evolved from scientific research into CD47 biology and macrophage checkpoint inhibition, positioning itself within a competitive field of next-generation immunotherapies. Its strategic differentiation has centered on the design of evorpacept’s inactive Fc domain, which is intended to reduce damage to healthy blood cells while preserving anti-tumor activity. Revenue generation has historically been limited, as the company remains in the clinical development stage and has not reported commercial product sales based on publicly available filings.